Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Bluejay Diagnostics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ACTON, MASS., OCT. 10, 2025 (GLOBE NEWSWIRE) -- BLUEJAY DIAGNOSTICS, INC. (NASDAQ: BJDX) (BLUEJAY OR THE COMPANY), A MEDICAL DIAGNOSTICS COMPANY DEVELOPING NEAR-PATIENT SOLUTIONS FOR CRITICAL CARE, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT FOR THE PURCHASE AND SALE OF AN AGGREGATE OF 2,250,000 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AND SERIES F WARRANTS TO PURCHASE UP TO 4,500,000 SHARES OF COMMON STOCK AT A PURCHASE PRICE OF $2.00 PER SHARE OF COMMON STOCK (OR PER PRE-FUNDED WARRANT IN LIEU THEREOF) AND ACCOMPANYING WARRANTS PRICED AT-THE-MARKET UNDER NASDAQ RULES. THE SERIES F WARRANTS HAVE AN EXERCISE PRICE OF $1.75 PER SHARE AND ARE EXERCISABLE IMMEDIATELY UPON ISSUANCE. THE SERIES F WARRANTS EXPIRE FIVE AND ONE-HALF YEARS FROM THE DATE OF ISSUANCE.

BLUEJAY DIAGNOSTICS ANNOUNCES CLOSING OF $4.5 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES

ACTON, MASS., OCT. 09, 2025 (GLOBE NEWSWIRE) -- BLUEJAY DIAGNOSTICS, INC. (NASDAQ: BJDX) (BLUEJAY OR THE COMPANY), A MEDICAL DIAGNOSTICS COMPANY DEVELOPING NEAR-PATIENT SOLUTIONS FOR CRITICAL CARE, TODAY ANNOUNCED THAT IT HAS ENTERED INTO DEFINITIVE AGREEMENTS FOR THE PURCHASE AND SALE OF AN AGGREGATE OF 2,250,000 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANT IN LIEU THEREOF) AND SERIES F WARRANTS TO PURCHASE UP TO 4,500,000 SHARES OF COMMON STOCK AT A PURCHASE PRICE OF $2.00 PER SHARE OF COMMON STOCK (OR PER PRE-FUNDED WARRANT IN LIEU THEREOF) AND ACCOMPANYING WARRANTS IN A PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES. THE SERIES F WARRANTS WILL HAVE AN EXERCISE PRICE OF $1.75 PER SHARE AND WILL BE EXERCISABLE IMMEDIATELY UPON ISSUANCE. THE SERIES F WARRANTS WILL EXPIRE 5.5 YEARS FROM THE DATE OF ISSUANCE. THE PRIVATE PLACEMENT IS EXPECTED TO CLOSE ON OR ABOUT OCTOBER 10, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

BLUEJAY DIAGNOSTICS ANNOUNCES $4.5 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES

ACTON, MASS. AND YAMANASHI, JAPAN, OCT. 09, 2025 (GLOBE NEWSWIRE) -- BLUEJAY DIAGNOSTICS, INC. (NASDAQ: BJDX) (BLUEJAY), A MEDICAL DIAGNOSTICS COMPANY FOCUSED ON DEVELOPING RAPID NEAR-PATIENT TESTING SOLUTIONS FOR CRITICAL CARE, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT TO AMEND THE MASTER SERVICE AGREEMENT AND THE MASTER SUPPLY AGREEMENT WITH SANYOSEIKO CO., LTD. (SANYOSEIKO), A JAPAN-BASED CONTRACT MANUFACTURER SPECIALIZING IN MEDICAL DEVICES AND PRECISION ENGINEERING.

BLUEJAY DIAGNOSTICS AND SANYOSEIKO EXPAND STRATEGIC PARTNERSHIP TO ADVANCE COMMERCIALIZATION OF SYMPHONY PLATFORM

ACTON, MASS., AUG. 07, 2025 (GLOBE NEWSWIRE) -- BLUEJAY DIAGNOSTICS, INC. (NASDAQ: BJDX) (BLUEJAY OR THE COMPANY), A MEDICAL DIAGNOSTICS COMPANY DEVELOPING NEAR-PATIENT SOLUTIONS FOR CRITICAL CARE, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025, AND PROVIDED AN UPDATE ON ITS SYMPHONY IL-6 TEST PROGRAM AND KEY OPERATIONAL MILESTONES.

BLUEJAY DIAGNOSTICS PROVIDES SECOND QUARTER BUSINESS AND CORPORATE UPDATE

ACTON, MASS., JUNE 03, 2025 (GLOBE NEWSWIRE) -- BLUEJAY DIAGNOSTICS, INC. (NASDAQ: BJDX) (BLUEJAY OR THE COMPANY), A MEDICAL DIAGNOSTICS COMPANY DEVELOPING RAPID NEAR-PATIENT TESTING SOLUTIONS FOR CRITICAL CARE, TODAY PROVIDED A 2025 MID-YEAR BUSINESS AND CORPORATE UPDATE.

BLUEJAY DIAGNOSTICS PROVIDES MID-YEAR BUSINESS AND CORPORATE UPDATE

NEW CLINICAL DATA FROM THE SYMON-I STUDY TO EVALUATE IL-6 IN SEPSIS PATIENTS TO BE PRESENTED. NEW CLINICAL DATA FROM THE SYMON-I STUDY TO EVALUATE IL-6 IN SEPSIS PATIENTS TO BE PRESENTED.

BLUEJAY ANNOUNCES ABSTRACT ACCEPTED FOR PRESENTATION AT THE 2025 SOCIETY OF ACADEMIC EMERGENCY MEDICINE (SAEM) ANNUAL MEETING

ACTON, MASS., APRIL 07, 2025 (GLOBE NEWSWIRE) -- BLUEJAY DIAGNOSTICS, INC.(NASDAQ: BJDX) (BLUEJAY OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY DEVELOPING RAPID DIAGNOSTICS ON ITS SYMPHONY PLATFORM TO IMPROVE PATIENT OUTCOMES IN CRITICAL CARE SETTINGS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT WITH INSTITUTIONAL INVESTORS THAT ARE EXISTING HOLDERS OF WARRANTS TO PURCHASE SHARES OF COMMON STOCK OF THE COMPANY FOR CASH (THE EXISTING WARRANTS), WHEREIN THE INVESTORS AGREED TO EXERCISE THE EXISTING WARRANTS TO PURCHASE UP 1,085,106 SHARES OF COMMON STOCK AT A REDUCED EXERCISE PRICE OF $3.42 PER SHARE, RESULTING IN GROSS PROCEEDS OF APPROXIMATELY $3.7 MILLION, BEFORE DEDUCTING OFFERING FEES AND OTHER EXPENSES PAYABLE BY THE COMPANY.

BLUEJAY DIAGNOSTICS ANNOUNCES ENTRY INTO WARRANT INDUCEMENT TRANSACTION FOR APPROXIMATELY $3.7 MILLION IN GROSS PROCEEDS

ACTON, MASS., NOV. 13, 2024 (GLOBE NEWSWIRE) -- BLUEJAY DIAGNOSTICS, INC. (NASDAQ: BJDX) (BLUEJAY OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY DEVELOPING RAPID DIAGNOSTICS ON ITS SYMPHONY PLATFORM TO IMPROVE PATIENT OUTCOMES IN CRITICAL CARE SETTINGS, TODAY ANNOUNCED THAT THE COMPANY'S BOARD OF DIRECTORS HAS APPROVED A REVERSE STOCK SPLIT OF ITS SHARES OF COMMON STOCK AT A RATIO OF 1-FOR-50 (THE REVERSE STOCK SPLIT). THE REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 12:01 A.M. EASTERN TIME ON NOVEMBER 18, 2024, AND THE COMPANY'S COMMON STOCK WILL OPEN FOR TRADING ON THE NASDAQ CAPITAL MARKET ON A POST-SPLIT BASIS ON NOVEMBER 18, 2024 UNDER THE COMPANY'S EXISTING TRADING SYMBOL, BJDX. AT SUCH TIME, THE COMPANY'S COMMON STOCK WILL ALSO COMMENCE TRADING WITH A NEW CUSIP NUMBER, 095633509.

BLUEJAY DIAGNOSTICS ANNOUNCES REVERSE STOCK SPLIT

ACTON, MASS., JUNE 28, 2024 (GLOBE NEWSWIRE) -- BLUEJAY DIAGNOSTICS, INC.(NASDAQ: BJDX) (BLUEJAY OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY DEVELOPING RAPID DIAGNOSTICS ON ITS SYMPHONY PLATFORM TO IMPROVE PATIENT OUTCOMES IN CRITICAL CARE SETTINGS, TODAY ANNOUNCED THE CLOSING OF A FIRM COMMITMENT UNDERWRITTEN PUBLIC OFFERING WITH GROSS PROCEEDS TO THE COMPANY EXPECTED TO BE APPROXIMATELY $8.75 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND OTHER ESTIMATED EXPENSES PAYABLE BY THE COMPANY. THE BASE OFFERING CONSISTED OF 5,368,098 COMMON UNITS OR PREFUNDED UNITS, EACH UNIT CONSISTING OF ONE SHARE OF THE COMPANY'S COMMON STOCK (COMMON STOCK) OR ONE PRE-FUNDED WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK (EACH, A PREFUNDED WARRANT), TWO CLASS C WARRANTS EACH TO PURCHASE ONE SHARE OF OUR COMMON STOCK (EACH, A CLASS C WARRANT) AND ONE CLASS D WARRANT TO PURCHASE SUCH NUMBER OF SHARES OF COMMON STOCK AS DETERMINED IN THE CLASS D WARRANT (EACH, A CLASS D WARRANT AND TOGETHER WITH THE CLASS C WARRANTS, THE COMMON WARRANTS). THE PURCHASE PRICE OF EACH COMMON UNIT IS $1.63, AND THE PURCHASE PRICE OF EACH PREFUNDED UNIT IS $1.6299 (WHICH IS EQUAL TO THE PUBLIC OFFERING PRICE PER COMMON UNIT MINUS $0.0001). THE PREFUNDED WARRANTS WILL BE IMMEDIATELY EXERCISABLE AND MAY BE EXERCISED AT ANY TIME UNTIL ALL THE PREFUNDED WARRANTS ARE EXERCISED IN FULL.

BLUEJAY DIAGNOSTICS ANNOUNCES CLOSING OF $8.75 MILLION UNDERWRITTEN PUBLIC OFFERING

RESULTS FROM PRIMARY ANALYSIS OF THE SYMON-I PILOT CLINICAL STUDY CONSISTENT WITH IL-6 AS A PREDICTOR OF PATIENTS WHO HAVE A MORTALITY EVENT WITH 28 DAYS AFTER SEPSIS AND SEPTIC SHOCK DIAGNOSIS AND ARE ADMITTED TO THE INTENSIVE CARE UNIT (ICU). RESULTS FROM PRIMARY ANALYSIS OF THE SYMON-I PILOT CLINICAL STUDY CONSISTENT WITH IL-6 AS A PREDICTOR OF PATIENTS WHO HAVE A MORTALITY EVENT WITH 28 DAYS AFTER SEPSIS AND SEPTIC SHOCK DIAGNOSIS AND ARE ADMITTED TO THE INTENSIVE CARE UNIT (ICU).

Bluejay Diagnostics, Inc.

BJDX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Bluejay Diagnostics, Inc.

BJDX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BJDX